We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 06, 2021

PAM50-Based Chemo-Endocrine Score in HR-Positive HER2-Positive Breast Cancer Treated With Neoadjuvant Therapy

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Independent Validation of the PAM50-Based Chemo-Endocrine Score in Hormonal Receptor Positive HER2-Positive Breast Cancer Treated With Neoadjuvant Therapy
Clin. Cancer Res 2021 Feb 25;[EPub Ahead of Print], T Pascual, A Fernandez-Martinez, M Tanioka, MV Dieci, S Pernas, J Gavilá, V Guarneri, J Cortés, P Villagrasa, N Chic, M Vidal, B Adamo, M Muñoz, G Griguolo, A Llombart-Cussac, P Conte, M Oliveira, B Conte, L Paré, P Galván, LA Carey, CM Perou, A Prat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading